



Contents lists available at ScienceDirect

International Immunopharmacology

journal homepage: www.elsevier.com/locate/intimp

Nicotine effect on inflammatory and growth factor responses in murine cutaneous wound healing

Q1 Sofia Xanthoulea ^{a,c,*}, An Deliaert ^a, Andrea Romano ^b, Sander S. Rensen ^c,
 4 Wim A. Buurman ^c, Rene' RWJ van der Hulst ^a

^a Department of Plastic Surgery, Maastricht University Medical Center, P.O. Box 5800, 6202 AZ, Maastricht, The Netherlands

^b GROW, School for Oncology and Developmental Biology, Maastricht University Medical Centre, Maastricht, The Netherlands

^c Department of Surgery, NUTRIM School for Nutrition, Toxicology & Metabolism, Maastricht University Medical Centre, Maastricht, The Netherlands

ARTICLE INFO

Article history:

Received 14 June 2013

Received in revised form 3 September 2013

Accepted 15 October 2013

Available online xxxx

Keywords:

Cytokines

Growth factors

Inflammation

Macrophages

Nicotine

Wound repair

ABSTRACT

The aim of the current study was to investigate the effect of nicotine in an experimental mouse model of cutaneous injury and healing responses, during the inflammatory phase of repair. Nicotine injection in full-thickness excisional skin wounds minimally affected inflammatory mediators like TNF, IL-6 and IL-12 while it induced a down-regulation in the expression of growth factors like VEGF, PDGF, TGF- β 1 and TGF- β 2, and the anti-inflammatory cytokine IL-10. Analysis of wound closure rate indicated no significant differences between nicotine and saline injected controls. *In-vitro* studies using bone marrow derived macrophages, resident peritoneal macrophages and RAW 264.7 macrophages, indicated that nicotine down-regulates TNF production. Moreover, nicotine was shown to down-regulate VEGF, PDGF and TGF- β 1 in both bone marrow derived macrophages and RAW 264.7 cells. Using an NF- κ B luciferase reporter RAW 264.7 cell line, we show that nicotine effects are minimally dependent on NF- κ B inhibition. Moreover, nicotinic acetylcholine receptor (nAChR) subunit expression analyses indicated that while β 2 nAChR subunit is expressed in mouse macrophages, α 7 nAChR is not. In conclusion, while skin inflammatory parameters were not significantly affected by nicotine, a down-regulation of growth factor expression in both mouse skin and macrophages was observed. Reduced growth factor expression by nicotine might contribute, at least in part, to the overall detrimental effects of tobacco use in wound healing and skin diseases.

© 2013 Published by Elsevier B.V.

1. Introduction

Cutaneous wound healing after an injury is a complex and highly dynamic process that involves interaction of different players like resident cells of the skin, inflammatory leukocytes, extracellular matrix components and soluble mediators. The healing process can be divided in three consecutive and partially overlapping phases i.e. inflammatory phase, proliferative phase and remodelling phase. The repair process finally results in the formation of a mass of fibrotic tissue known as scar [1,2].

Numerous experimental and clinical studies have determined that inflammation plays a crucial although still not completely clear role during cutaneous wound healing and influences the quality of the resulting scar. Inflammatory cells and particularly macrophages appear to be essential for proper healing by, among other mechanisms, stimulating

growth factor and anti-inflammatory cytokine production that are necessary for repair [3]. Moreover, pathological functioning of macrophages and excessive inflammation in the wound healing process can result in derailed healing, like the formation of ulcers, chronic wounds, hypertrophic scars and keloids [4].

Nicotine, a major constituent of tobacco smoke, has been shown to exert anti-inflammatory effects on different cell types and to be beneficial in disorders where inflammation-related mechanisms are involved like in ulcerative colitis and obesity [5]. Nicotine actions are mediated through binding to cholinergic receptors termed nicotinic acetylcholine receptors (nAChR) that are expressed in many different tissues and cells in the body, including immune cells. In both human and mouse macrophages, nicotine was shown to inhibit the release of pro-inflammatory cytokines through a specific "nicotinic anti-inflammatory pathway" that involves signalling through the α 7 nAChR and prevents activation of the NF- κ B pathway [6–9]. In human microvascular endothelial cells, nicotine was found to inhibit TNF-induced NF- κ B activation, to suppress adhesion molecule and chemokine expression and to reduce adhesion of leukocytes to activated endothelium and consequent inflammation [10]. Moreover, nicotine was shown to have angiogenic effects and to increase endothelial cell proliferation and vascular growth in different *in-vitro* and *in-vivo* models [11,12].

Abbreviations: TNF, tumor necrosis factor; IL-6, interleukin 6; IL-12, interleukin 12; VEGF, vascular endothelial growth factor; PDGF, platelet derived growth factor; TGF- β 1, transforming growth factor beta 1; TGF- β 2, transforming growth factor beta 2.

* Corresponding author at: Maastricht University Medical Centre, Universiteitssingel 50, Maastricht 6229 ER, The Netherlands. Tel.: +31 433882128; fax: +31 433884154.

E-mail address: sofia.xanthoulea@maastrichtuniversity.nl (S. Xanthoulea).

In the skin, effects of nicotine are ambivalent and often unclear, but they generally appear more negative than positive. Although cigarette smoking has been reported to negatively affect cutaneous wound healing [13], the angiogenic action of nicotine prompted for studies for a potential beneficial role of nicotine in this process. It was reported that in either normal C57BL/6 [14] or genetically diabetic mice [15], nicotine promotes wound healing due to increased angiogenesis. Yet the effect of nicotine administration on wound inflammatory responses was not evaluated in these studies. Moreover, we have observed that scar formation, a process largely dependent on the extent of the preceding inflammatory process [16], appears to be improved in smokers, which tend to have faster and less erythematous scar healing compared to non-smokers [17].

In the present study, we aimed to evaluate the effect of nicotine during the inflammatory phase of cutaneous wound healing responses in mice. Quantification of wound closure rate indicated that nicotine did not significantly affect the wound healing process. However, nicotine administration in wounds was found to negatively regulate the production of growth factors like VEGF, PDGF, TGF- β 1 and TGF- β 2 but to only minimally affect wound inflammatory parameters. *In-vitro*, in both primary mouse macrophages and in the macrophage cell line RAW 264.7, nicotine was also found to induce a down-regulation of growth factor expression and to decrease TNF production. Nicotine mediated effects were found to be independent of NF- κ B inhibition and the expression of the α 7 nAChR.

2. Materials and methods

2.1. Animals and wound model

Ten to twelve weeks old C57BL/6 female mice ($n = 3-4$ mice/group) were used for experiments. To generate wounds, mice were anesthetized by isoflurane inhalation and the dorsal surface was shaved and cleaned with 70% ethanol. Full-thickness excisional skin wounds were generated on either side of the dorsal midline using a 3 mm biopsy punch (Kai medical). Mice were housed individually in special paper bedding material (7089 Harlan Teklad Diamond Soft Bedding), to avoid bedding particles interfering with the healing wounds. Two wounds were generated on the same animal and mice were divided in groups. Mice in each group received only one treatment in both wounds (i.e. saline or nicotine solutions). Solutions were injected with 3 injections of 20 μ l (total 60 μ l) around the wounds once daily for 3 days. Wounds were photographed daily and wound area was quantified using Image J. The percentage of wound closure was calculated using the following formula: Wound closure (%) = [(wound area on day 0 – wound area on indicated day)/wound area on day 0] \times 100. At sacrifice, wounds were excised and snap frozen in liquid N₂.

Experiments were performed twice. Mice were maintained under standard pathogen-free conditions and all experiments were approved by the Committee for Animal Welfare of Maastricht University. The investigation conforms to the *Guide for the Care and Use of Laboratory Animals* published by the US National Institutes of Health (NIH Publication No. 85-23, revised 1996).

2.2. Reagents

Nicotine (N3876) and LPS (L2630) were from Sigma-Aldrich Chemie BV (Zwijndrecht, The Netherlands). Nicotine solutions were prepared in culture medium or PBS and were made fresh prior to each experiment. ELISA kits for murine IL-6, IL-10 and IL-12 were purchased from Invitrogen Life Technologies, Inc. (Carlsbad, CA, USA) and performed according to manufacturer's protocol. For murine TNF ELISA a hamster anti-murine TNF monoclonal (TN3) was used as capture antibody and a polyclonal rabbit anti-murine TNF (Genzyme Corporation, Cambridge, MA, USA) was used as a second antibody. The ELISA had a lower detection limit of 50 pg/ml. Quantikine TGF- β 1 and PDGF-AB ELISA kits (R&D systems) and VEGF ELISA kit (Life Technologies) were performed according to manufacturer's protocol.

2.3. Primary cell isolation and cell lines

For generation of bone marrow derived macrophages (BMDM), 145 bone marrow was isolated from femur and tibia bones of C57BL/6 146 mice and cultured in 15-cm bacteriologic plastic petri dishes in RPMI 147 1640 supplemented with 10% heat inactivated fetal bovine serum, 100 148 U/ml penicillin, 100 μ g/ml streptomycin, 2 mM L-glutamine, 10 mM 149 Hepes and 15% L-929 cell conditioned medium (LCM) for 8 days. 150 Resident peritoneal macrophages (RPM) were collected from C57BL/6 151 mice by flushing the peritoneal cavity with 5 ml of ice cold medium. 152 Peritoneal cells were plated in RPMI medium supplemented with anti- 153 biotics, L-glutamine and 10% FCS and macrophages were left to adhere 154 for 4 h. Cells were washed and the remaining macrophages were 155 cultured overnight and stimulated the next day with nicotine and/or LPS 156 for the indicated times. RAW 264.7 cells (American Type Culture Collec- 157 tion, number TIB-71) were cultured in RPMI medium supplemented 158 with antibiotics, L-glutamine and 10% FCS. 3 T3-L1 murine fibroblasts 159 (American Type Culture Collection, number CL-173) were cultured in 160 DMEM supplemented with antibiotics, L-glutamine and 10% FCS and 161 SVEC4-10 small-vessel murine endothelial cells (ATCC number CRL- 162 2181) were cultured in F12 medium supplemented with antibiotics 163 and 10% FCS. RAW 264.7 cells stably transfected with the 3 \times - κ B-*luc* 164 plasmid [18] were a generous gift from Dr. M. de Winther (AMC, 165 Amsterdam). 166

Table 1

Primer sequences used in this study.

Primer name	Forward sequence	Reverse sequence
CD-68	5'-TGACCTGCTCTCTAAGGCTACA-3'	5'-TCACGGTTGCAAGAGAACATG-3'
TNF	5'-CATCTTCTCAAATTCGAGTGACAA-3'	5'-TGGGAGTAGACAAGGTACAACCC-3'
IL-6	5'-TTCAACCAAGAGGTAAGATTTACATAA-3'	5'-CACTCCTTCTGTGACTCCAGCTT-3'
IL-12	5'-TGAGAACTACAGCACCAGCTTCT-3'	5'-CTTCAAAGGCTTCATCTGCAAGT-3'
IL-10	5'-GCTCTACTGACTGGCATGAG-3'	5'-CGCAGCTCTAGGAGCATGTG-3'
VEGF	5'-GCCTTACTGCTGACTCCACCA-3'	5'-GGGACTTCTGCTCTCTTCTGTG-3'
PDGF	5'-CGCCTGCAAGTGTGAGACAG-3'	5'-GAATGGTCACCCGAGCTTGA-3'
TGF- β 1	5'-GCCCTTCTGCTCTCATG-3'	5'-CCGCACACAGCAGTCTTCTC-3'
TGF- β 2	5'-GACTAACATCTCCACCCA-3'	5'-CCATCAATACCTGCAATCTCG-3'
α 7 nAChR-1	5'-CACATCCACACCAACGCTT-3'	5'-AAAAGGGAACACAGCTACATC-3'
α 7 nAChR-2	5'-TGCTGGTATTCTTGTGCGCTGC-3'	5'-GGTGTGCGGAAGTACTGTGCTAT-3'
α 7 nAChR-3	5'-GCCTAAGTGACACAGGATCA-3'	5'-CTCGGAAGCAATGTAGAGC-3'
β 2 nAChR	5'-GGGCAGGCACACTATTCTTC-3'	5'-TCCAATCTCCCTCACACTC-3'
cyclophilin	5'-TTCCTCTTTCACAGAATTATCCA-3'	5'-CCGCCAGTGCATTATGG-3'
GAPDH	5'-TTCACCACATGGAGAAGGC-3'	5'-GGCATGGACTGTGGTCATGA-3'
β -actin	5'-GACAGGATGCAGAAGGAGATTACTG-3'	5'-CCACCGATCCACACAGAGTACTT-3'




Fig. 1. Nicotine administration in wounds. (A) Macroscopic appearance of representative saline, 10⁻⁸ M and 10⁻⁴ M nicotine injected wounds. Day 0 pictures were taken immediately after wounding. (B) Quantification of wound closure rate. At the indicated days, wound areas were determined using image analysis and expressed as percentage of wound area immediately post-injury as described in methods ($n = 6-8$ wounds/group). (C) mRNA expression analysis by real-time PCR of CD-68, IL-12, TNF, IL-6, IL-10 and (D) VEGF, PDGF, TGF- β 1, TGF- β 2 in either unwounded (NMS, normal mouse skin) or wounded skin, after three days from wounding. Unwounded skin expression levels for each gene were set to one and for simplicity only one control is shown. $n = 3$ mice/group. (E) mRNA expression analysis by real-time PCR of CD-68, IL-12, TNF, IL-6, IL-10 and (F) VEGF, PDGF, TGF- β 1, TGF- β 2 in wounded skin after three days from wounding, injected with either saline or nicotine solutions (10⁻⁴ M or 10⁻⁸ M). Expression levels for each gene in unwounded (NMS, normal mouse skin) were set to one. $n = 3-4$ mice/group. Statistical significance was evaluated for each nicotine concentration compared to saline control or between wounded and non wounded skin, by t -test. * $p < 0.05$, ** $p < 0.01$.

2.4. RNA isolation and quantitative gene expression

RNA was isolated either with the RNeasy Fibrous Tissue kit (Qiagen GmbH, Hilden, Germany) for mouse skin tissue or with Trizol (Sigma-Aldrich Chemie BV) for cell monolayers. Residual DNA was digested with the RQ1 RNase-free DNase (Promega GmbH, Mannheim, Germany) and cDNA synthesis was performed using the iScript™ cDNA synthesis kit (Bio-Rad, Hercules, CA, USA). Quantitative PCR was performed in 10 ng of cDNA, with 1 × Absolute qPCR SYBR Green Fluorescein Mix (Westburg, Leusden, The Netherlands) and 150 nM of gene specific forward and reverse primers. Cyclophilin A and β-actin were used as housekeeping genes. Primer sequences are indicated in Table 1.

2.5. MTT assay, luciferase activity and ELISA

For MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide; Sigma-Aldrich Chemie BV) assay, 10⁵ cells/well of BMDM, RAW 264.7, PEC or 5 × 10⁴ cells/well of SVEC4-10 or 10⁴ cells/well of 3 T3-L1 cells were plated in 96-well plates overnight and stimulated the following day with nicotine and/or LPS (100 ng/ml) for 24 h. Nicotine was added to cell cultures 30 min before LPS. MTT assay was performed after 24 h by addition of MTT solution to a final concentration of 0.5 mg/ml, for 2 h. Dye was solubilized with DMSO (Sigma-Aldrich Chemie BV) and absorbance was measured at 570 nm. Data represent mean ± SEM of 4 independent experiments performed in triplicate.

For luciferase activity, RAW 264.7 cells stably transfected with the 3x-κB-luc plasmid were plated at a density of 10⁵ cells/well in 96 well plates and stimulated with the indicated compounds for the indicated

times. Cells were lysed in lysis buffer (Promega GmbH) for 20 min and 10 μl lysate was added to 50 μl luciferin (Steady-Glo Luciferase assay system, Promega GmbH). Luciferase activity was measured with a Lumac Biocounter M1500 luminometer (Promega GmbH). Data represent mean ± SEM of 2 independent experiments performed in quadruplicate.

For ELISA, 2 × 10⁵ T3-L1 fibroblast cells or 5 × 10⁵ macrophages or SVEC4-10 endothelial cells were plated in 500 μl medium in triplicate/condition in 24-well plates and stimulated for 6 or 24 h with nicotine and/or LPS. Supernatants were analyzed by ELISA. Since significant levels of growth factors are present in bovine serum used in tissue culture medium, for quantification of VEGF, PDGF-AB and TGF-β1 in macrophage supernatants, medium was changed to Optimem-1 (Gibco-BRL) overnight and cells were stimulated the following morning with nicotine for 6 or 24 h. Experiments were performed in triplicate and data represent mean ± SEM of 3 independent experiments.

2.6. Statistical analysis

Statistical analyses were performed using Graphpad Prism (Graphpad Software) or SigmaPlot statistical tests. Data are expressed as means ± SEM. A p < 0.05 is considered statistically significant.

3. Results

3.1. Nicotine down-regulates growth factor expression in skin wounds

The initial response upon a cutaneous injury is characterized by a strong inflammatory reaction with induction of different inflammatory




Fig. 2. Nicotine down-regulates TNF production by mouse macrophages. ELISA for (A) TNF, (B) IL-6, (C) IL-10 and (D) IL-12 in culture supernatants of either mouse bone marrow derived macrophages (BMDM), resident peritoneal macrophages (RPM) or RAW 264.7 macrophages stimulated with 100 ng/ml LPS in the presence or absence of different doses of nicotine (10⁻⁴ M, 10⁻⁶ M, 10⁻⁸ M), after 24 h. Left Y axis shows protein levels for BMDM and either RPM or RAW 264.7 cells. Right Y axis shows protein levels for RAW 264.7 or RPM cells. * p < 0.05, ** p < 0.01. Statistical significance was evaluated for each nicotine concentration compared to no nicotine control by t-test.

mediators. Since nicotine was previously shown to negatively regulate inflammation [6–9], and to promote wound healing in normal [14] and genetically diabetic mice [15], we aimed to examine the effect of nicotine administration during the inflammatory phase of cutaneous wound healing in mice. Full thickness excisional wounds were generated on the dorsum of C57BL/6 mice and mice were divided in groups that received either saline or nicotine solutions. Saline or nicotine solutions at two different concentrations (10^{-4} M or 10^{-8} M) were injected around the wounds daily for three days, similar to other studies [14] and as described in the methods section. Quantification of wound area indicated a not significant delay in wound closure in the nicotine injected wounds compared to saline controls (Fig. 1 A and B). After three days, real time PCR analysis of RNA isolated from either wounded mice or non-wounded controls (normal mouse skin, NMS) was performed. As shown in Fig. 1 C, wounded skin exhibits a strong inflammatory response which is absent in non-wounded controls. CD-68 was over five-fold increased indicating extensive macrophage infiltration and expression of different inflammatory mediators (TNF, IL-6, IL-10) was also found several fold increased (Fig. 1C). A milder effect of wounding on expression of growth factors was observed (Fig. 1D).

Nicotine injections resulted in significant mild down-regulation in the expression of IL-10 in the wounds of 10^{-8} M nicotine injected wounds compared to saline controls (Fig. 1E). Interestingly, nicotine administration indicated a clear down-regulation in the mRNA expression of growth factors, with PDGF, TGF- β 1 and TGF- β 2 showing significant differences while VEGF expression had a similar trend but differences were borderline not significant (Fig. 1F).

3.2. Nicotine down-regulates TNF and growth factor expression in mouse macrophages

Macrophages play a crucial role during cutaneous wound healing and represent a major source of cytokines and growth factors in the wound [3]. Previous studies have shown that nicotine attenuates macrophage activation and inhibits the production of a number of pro-inflammatory cytokines [7,9]. To evaluate the effect of nicotine in our setting, we used primary mouse macrophages like bone marrow derived (BMDM) and resident peritoneal macrophages (RPM) and the mouse macrophage cell line RAW 264.7. Cells were stimulated with LPS in order to induce cytokine production, and with or without addition of nicotine in the culture medium (nicotine added 30 min. before LPS) for either 6 or 24 h. Nicotine concentrations used were comparable to those in similar studies [7,9] and in the range of nicotine concentrations in blood during smoking [19]. No major effect of nicotine on the production of TNF, IL-6, IL-12 and IL-10 was observed after 6 h, as measured by ELISA in culture supernatants (data not shown). However after 24 h, we could confirm previous studies showing that nicotine induces a significant dose-dependent down-regulation in the production of TNF in all macrophage cells tested (Fig. 2A). No significant effect of nicotine on the production of IL-6, IL-10 or IL-12 was observed (Fig. 2B, C, D).

Since macrophages are major sources of growth factors and nicotine administration in wounds indicated a down-regulation in growth factor expression, we analyzed macrophage growth factor gene expression in the presence of nicotine. Similar to the *in-vivo* findings, nicotine was




Fig. 3. Nicotine inhibits growth factor expression in mouse macrophages. mRNA expression analysis by real-time PCR of VEGF, PDGF, TGF- β 1 and TGF- β 2 in either (A) bone marrow derived macrophages or (B) RAW 264.7 macrophages stimulated with nicotine (10^{-4} M, 10^{-6} M, 10^{-8} M), after 24 h. Expression levels in cells not stimulated with nicotine (no nic.) for each gene were set to one and for simplicity only one control is shown. (C) ELISA for VEGF, PDGF and TGF- β 1 in culture supernatants of mouse bone marrow derived macrophages not stimulated or stimulated with nicotine (10^{-4} M, 10^{-8} M) for 24 h. (D) MTT assay performed in bone marrow derived macrophages (BMDM), resident peritoneal macrophages (RPM) or RAW 264.7 macrophages in the presence of different doses of nicotine (10^{-4} M, 10^{-6} M, 10^{-8} M), after 24 h. * $p < 0.05$, ** $p < 0.01$. Statistical significance was evaluated for each nicotine concentration compared to no nicotine control by *t*-test.

found to down-regulate mRNA levels of VEGF, PDGF and TGF- β 1 in BMDM and RAW 264.7 macrophages (Fig. 3A and B respectively) (TGF- β 2 levels were undetectable). A comparable down-regulation in the protein levels of VEGF, PDGF and TGF- β 1 was measured in BMDM culture supernatants after 24 h of incubation with nicotine (Fig. 3C). Expression levels were below detection limit in supernatants of RAW 264.7 cells. Cell viability measurement by tetrazolium salt MTT assay showed that concentrations of nicotine used did not result in significant differences in cell survival and therefore the observed effects were not due to cytotoxicity (Fig. 3D).

3.3. Nicotine does not significantly affect NF- κ B transcriptional activity in mouse macrophages

Nicotine has been proposed to inhibit pro-inflammatory gene expression through a nicotinic anti-inflammatory pathway which results in the inhibition of NF- κ B [8,20]. Moreover, NF- κ B regulates the expression of a number of growth factors as VEGF and PDGF [21]. To determine the effect of nicotine on NF- κ B transcriptional activity we used a macrophage RAW 264.7 cell line stably transfected with an NF- κ B luciferase reporter and that expresses luciferase under the control of NF- κ B. This cell line maintains the inflammatory characteristics of the parental line used in the previous experiments [18]. As shown in Fig. 4A, nicotine

alone (without LPS induction), does not activate NF- κ B in any of the concentrations or time points examined (1, 6 or 24 h; for simplicity only the one hour time point is shown). Activation of RAW 264.7 macrophages with LPS induces NF- κ B activation already after one hour, as measured by luciferase activity. NF- κ B transcriptional activity peaked at six hours and returned to baseline after 24 h. However, nicotine showed only a very mild and statistically non-significant reduction in NF- κ B activity at one and six hours indicating that NF- κ B inhibition by nicotine is only minimal.

Since nicotine dependent NF- κ B inhibition in human macrophages was reported to be mediated by the α 7 nicotinic acetylcholine receptor (α 7 nAChR) [8,20], we evaluated the expression of this receptor in the different macrophage cell types used in our study. RNA was isolated from BMDM, RPM and RAW 264.7 cells and PCR was performed on cDNA for the identification of nAChR transcripts. As shown by previous studies [22], while expression of another nicotinic receptor like β 2 nAChR was detected in mouse macrophages, α 7 nAChR transcript was not detected in any of cell types analyzed (Fig. 4B). Use of two additional primer pairs for the α 7 nAChR failed as well to detect transcripts for this receptor (data not shown; primer sequences listed in Table 1). Similar analysis of RNA isolated from either unwounded or wounded mouse skin confirmed the presence of β 2 nAChR and the absence of α 7 nAChR transcripts in mouse skin.




Fig. 4. Minimal inhibition of NF- κ B transcriptional activity by nicotine. (A) Luciferase assay performed in RAW 264.7 macrophages stably transfected with an NF- κ B luciferase reporter, stimulated for 1, 6 or 24 h with 100 ng/ml LPS in the presence or absence of different doses of nicotine (10^{-4} M, 10^{-6} M, 10^{-8} M). In the absence of LPS, no luciferase activity was detected (for simplicity only the 1 h time point is shown). Statistical significance was evaluated for each nicotine concentration compared to no nicotine control by *t*-test. (B) RT-PCR showing transcript expression of nAChR α 7 and β 2 subunits in RNA derived from mouse brain, bone marrow derived macrophages (BMDM), resident peritoneal macrophages (RPM) or RAW 264.7 macrophages not stimulated or stimulated for 24 h with 100 ng/ml LPS, and in unwounded or day 3 wounded mouse skin. RNA derived from mouse brain was used as a positive control for nicotinic acetylcholine receptor expression while GAPDH was used as loading control.

314 3.4. Nicotine effect on endothelial and fibroblast cells

315 In addition to macrophages, fibroblasts and endothelial cells are
 316 abundantly present in the skin and have pivotal functions in the process
 317 of cutaneous wound healing. To evaluate the effect of nicotine on these
 318 cell types, we analyzed cytokine responses in the murine endothelial
 319 cell-line SVEC4-10 and in 3 T3-L1 murine fibroblasts after LPS activation
 320 in the presence or absence of nicotine (nicotine added to the medium
 321 30 min before LPS). In both cell types no detectable amounts of TNF,
 322 IL-12 or IL-10 were measured by ELISA after 24 h of either LPS or LPS
 323 and nicotine incubation (not shown). On the contrary, IL-6 was mea-
 324 sured in the culture supernatants of both SVEC4-10 cells (Fig. 5A) and
 325 3 T3-L1 fibroblasts (Fig. 6A), but no differences were seen in the pres-
 326 ence of different nicotine concentrations. MTT toxicity assay showed
 327 that the concentrations of nicotine used (10^{-4} M, 10^{-6} M, 10^{-8} M)
 328 were not toxic to either cell line since toxicity effects were only seen
 329 from concentrations higher than 10^{-3} M (Figs. 5B and 6B). Contrarily,
 330 MTT assay showed that nicotine actually promoted proliferation of
 331 3 T3-L1 fibroblasts. As shown in Fig. 6B, in the absence of LPS stimula-
 332 tion, nicotine induces an approximately 10–20% increase in cell prolifera-
 333 tion compared to non-treated cells. Addition of LPS to 3 T3-L1 cells
 334 induces a similar increase in cell proliferation but there is no further
 335 increase if nicotine is added in the presence of LPS.

336 To evaluate $\alpha 7$ nAChR expression in 3 T3-L1 and SVEC4-10 cells,
 337 RNA was isolated from either non-stimulated cells or cells stimulated
 338 with LPS for 24 h and cDNA was synthesized. Neither cell type was
 339 found to express $\alpha 7$ nAChR mRNA (Figs. 5C and 6C). SVEC4-10 cells
 340 expressed the $\beta 2$ nAChR transcripts while this nicotinic receptor
 341 subunit was absent from 3 T3-L1 fibroblasts. Moreover, real-time PCR
 342 analysis of RNA isolated from nicotine stimulated SVEC4-10 or 3 T3-L1

343 cells indicated that contrary to macrophages, nicotine does not induce
 344 a significant down-regulation of growth factors in these cell-types and
 345 actually shows a trend towards increased PDGF expression in 3 T3-L1
 346 cells (Figs. 5D and 6D respectively).

4. Discussion 347

348 The discovery approximately a decade ago of a nicotinic anti-
 349 inflammatory pathway mediated by the $\alpha 7$ nAChR has raised interest
 350 in the use of nicotine or nicotinic agonists as potential therapeutic
 351 agents in different chronic inflammatory conditions. The therapeutic
 352 use of nicotine has been suggested for the treatment of inflammatory
 353 disorders such as Crohn's disease, ulcerative colitis and obesity [5,23].
 354 However, the potential of a therapeutic role of nicotine in the skin is
 355 unclear and controversies exist as to whether the overall effect must
 356 be regarded as positive or negative [13].

4.1. Effect of nicotine on wound healing 357

358 Previous studies regarding the effect of nicotine in cutaneous wound
 359 healing responses in mice have shown contradictory results. In one
 360 study, day eight wounds treated with 10^{-3} M nicotine solution resulted
 361 in delayed wound healing with a larger wound area compared to saline
 362 controls, while wounds treated with a nicotine concentration of 10^{-4} M
 363 showed improved healing and a smaller wound area. Treatment with
 364 nicotine concentrations of 10^{-7} M or 10^{-10} M showed no signifi-
 365 cant differences [14]. In a different study, nicotine concentrations
 366 of 10^{-8} M and 10^{-9} M accelerated wound healing only in genetically
 367 diabetic (*Lepr^{db}*) mice but not in control mice (heterozygous for the
 368 diabetes allele) compared to saline treated controls [15]. In both studies,




Fig. 5. Analysis of nicotine action on SVEC4-10 murine endothelial cells. (A) ELISA for IL-6 in supernatants of SVEC4-10 cells stimulated with 100 ng/ml LPS in the presence or not of different doses of nicotine (10^{-4} M, 10^{-6} M, 10^{-8} M), after 24 h. (B) MTT assay performed in SVEC4-10 cells in the presence or absence of different doses of nicotine (10^{-4} M, 10^{-6} M, 10^{-8} M) and not stimulated or stimulated with 100 ng/ml LPS, after 24 h. (C) RT-PCR showing transcript expression of nAChR $\alpha 7$ and $\beta 2$ subunits in RNA derived from mouse brain and SVEC4-10 cells stimulated or not for 24 h with 100 ng/ml LPS. (D) mRNA expression analysis by real-time PCR of VEGF, PDGF, TGF- $\beta 1$ and TGF- $\beta 2$ in SVEC4-10 cells in the presence of different doses of nicotine (10^{-4} M, 10^{-6} M, 10^{-8} M), after 24 h. Statistical significance was evaluated for each nicotine concentration compared to no nicotine control by *t*-test.

369 improved healing was associated with improved wound angiogenesis.
 370 In our wound healing experiment we could not observe an improve-
 371 ment in wound healing induced by nicotine treatment in wild type
 372 mice compared to controls. Differences with previous studies regard
 373 both the background of the mice but also the time-point in which
 374 wound area is measured (the first three days in our setting versus
 375 days eight or fourteen in other studies). Although no significant dys-
 376 regulation in wound inflammatory parameters like TNF, IL-6 and IL-12
 377 was detected, nicotine induced a down-regulation in the expression of
 378 anti-inflammatory IL-10 and growth factors like VEGF, PDGF, TGF- β 1
 379 and TGF- β 2. This latter effect was also confirmed *in-vitro* in both primary
 380 mouse bone marrow derived macrophages and RAW 264.7 cells, at
 381 both the RNA and protein levels, while a similar down-regulation was
 382 not observed in either fibroblasts or endothelial cells. Therefore, it is
 383 likely that the inhibition of growth factor production by wound macro-
 384 phages accounts for the down-regulation of growth factors observed in
 385 nicotine-injected wounds.

386 4.2. Nicotine action on growth factor expression

387 Previous studies have suggested that the effect of nicotine on growth
 388 factor expression is likely to be cell-type specific. Chronic exposure to
 389 nicotine was found to reduce plasma VEGF levels in mice and to impair
 390 cholinergic angiogenesis [24]. In other studies, while nicotine was
 391 shown to induce VEGF and FGF in vascular smooth muscle cells and
 392 endothelial cells [25–27], it inhibited VEGF, PDGF and TGF- β 1 in rabbit
 393 osteoblasts [28] and VEGF in porcine retinal pigment epithelium [29].
 394 Moreover, nicotine was shown to upregulate the expression of VEGF
 395 but suppress the expression of PDGF in nasopharyngeal carcinoma
 396 (NPC) cells [30]. Our data show that in macrophages, a major source

of growth factors like VEGF and TGF- β 1 in wounds [31], the effect of
 nicotine is inhibitory. In support of a cell-type specific nicotine action,
 we observed a trend towards increased PDGF production by nicotine
 in 3 T3-L1 fibroblasts.

4.3. Nicotine action on monocytes/macrophages

Nicotine was found to inhibit the production of pro-inflammatory
 cytokines in human and mouse monocytes or macrophages through
 activation of a Jak2-STAT3 pathway and inhibition of the NF- κ B tran-
 scriptional activity [6–9,20]. However, discrepancies from these find-
 ings in studies where nicotine was shown to augment TNF and pro-
 inflammatory synthesis in macrophages exist [32]. Using either primary
 mouse cells like bone marrow derived macrophages and resident peri-
 toneal macrophages, or the mouse macrophage cell line RAW 264.7,
 we could confirm previous findings of an inhibitory action of nicotine
 on TNF production. Using an NF- κ B luciferase reporter system, we
 also show that, although nicotine induces down-regulation of TNF ex-
 pression in RAW 264.7 macrophages, this is only minimally dependent
 on inhibition of NF- κ B transcriptional activity. Discrepancies from other
 studies [8,20] that show inhibition by nicotine of NF- κ B activity in
 luciferase assays may be explained by the differences in transiently
 transfected cells used in those studies compared to the stable transfected
 line we used in our experiments. Therefore, additional mechanisms to
 NF- κ B suppression seem to be responsible for the nicotine induced
 down-regulation of TNF expression in macrophages. In line with this, a
 different mechanism of nicotine mediated suppression of TNF release
 in human macrophages was recently reported, through induction of
 tristetrarprolin (TTP), an ARE-binding protein that binds and promotes
 degradation of the TNF transcript [33].




Fig. 6. Analysis of nicotine action on 3 T3-L1 murine fibroblasts. (A) ELISA for IL-6 in supernatants of 3 T3-L1 cells stimulated with 100 ng/ml LPS in the presence or absence of different doses of nicotine (10⁻⁴ M, 10⁻⁶ M, 10⁻⁸ M), after 24 h. (B) MTT assay performed in 3 T3-L1 cells in the presence or absence of different doses of nicotine (10⁻⁴ M, 10⁻⁶ M, 10⁻⁸ M) and stimulated or not with 100 ng/ml LPS, after 24 hours. (C) RT-PCR showing transcript expression of nAChR α 7 and β 2 subunits in RNA derived from mouse brain and 3 T3-L1 cells stimulated or not for 24 h with 100 ng/ml LPS. (D) mRNA expression analysis by real-time PCR of VEGF, PDGF, TGF- β 1 and TGF- β 2 in 3 T3-L1 cells in the presence of different doses of nicotine (10⁻⁴ M, 10⁻⁶ M, 10⁻⁸ M), after 24 h. * $p < 0.05$. Statistical significance was evaluated for each nicotine concentration compared to no nicotine control by *t*-test.

4.4. Nicotinic acetylcholine receptor expression

The anti-inflammatory effect of nicotine is considered to be mediated by the $\alpha 7$ nAChR expressed by many different cell types ranging from neurons to immune cells. Regarding the skin, the $\alpha 7$ nAChR has been detected in the upper spinous and granular layers of human scalp epidermis [34] and in skin of BALB/c mice, where $\alpha 7$ nAChR positive staining was observed in epidermis, hair follicles, sebaceous glands, endothelial cells, resident dermal fibroblasts, but also in inflammatory cells like macrophages and PMNs during skin wound healing [35]. However, concerns have been raised regarding the specificity of anti- $\alpha 7$ nAChR antibodies due to the discrepancies in the results between immunodetection data and mRNA or genotyping results in $\alpha 7$ nAChR deficient mice [22,36,37]. Using three different primer pairs, we were unable to detect mRNA of $\alpha 7$ nAChR in either unwounded or wounded skin in C57BL/6 mice or in primary mouse cells or cell-lines. Our results are supported by similar studies that show presence of other nAChR transcripts like the $\beta 2$ nAChR but absence of the $\alpha 7$ nAChR mRNA in mouse alveolar [38,39], intestinal, splenic or peritoneal macrophages [22]. Since $\alpha 7$ nAChR has been detected in human monocytes, macrophages, endothelial cells [6,10,12] but not in the corresponding mouse cells, it is likely that expression patterns of nicotinic acetylcholine receptors may differ between human and mouse tissues or between different mouse strains, and comparison of different studies or translation of mouse studies to humans should be done with caution.

Finally, to evaluate the effect of nicotine on additional cell types present in the skin, we have used the mouse vascular endothelial cell line SVEC4-10 and the 3 T3-L1 murine fibroblast cell line. In both cell types nicotine was found to have no effect on IL-6 secretion, the only cytokine among TNF, IL-12 and IL-10 that was produced after LPS stimulation. However, we observed that nicotine induced a mild increase in cell proliferation in 3 T3-L1 fibroblasts under non-LPS stimulated conditions. This effect is potentially mediated by nicotinic acetylcholine receptor subunits expressed by fibroblasts that are different from $\alpha 7$ nAChR or $\beta 2$ nAChR since expression analysis indicated absence of these subunits in mouse 3 T3-L1 cells. Similar nicotine-induced stimulation in cell proliferation was noted by others in endothelial cells [40,41], bone cells [42], epithelial cells [43], and chondrocytes [44].

Taken together, our results show that during the inflammatory phase of murine cutaneous wound healing, the main effect of nicotine administration was a negative regulation of growth factor expression, an effect which is likely to be due to reduced growth factor expression by wound macrophages. The inhibitory effect of nicotine on growth factor production may reflect, to a certain degree, the damaging effects of smoking on the skin vasculature and oxygenation and may provide critical insight into the overall detrimental effects of tobacco use in wound healing and general skin diseases.

Funding

This study was supported by internal funds of the Maastricht University Medical Centre.

Acknowledgements

We wish to thank Dr. M.P.J. de Winther (AMC, Amsterdam University) for providing us with the RAW 264.7 NF- κ B luciferase reporter line and Dr. P.J. Lindsey (MUMC, Maastricht University) for help with statistical analysis.

References

- [1] Singer AJ, Clark RA. Cutaneous wound healing. *N Engl J Med* 1999;341:738–46.
- [2] Gurtner GC, Werner S, Barrandon Y, Longaker MT. Wound repair and regeneration. *Nature* 2008;453:314–21.

- [3] Eming SA, Krieg T, Davidson JM. Inflammation in wound repair: molecular and cellular mechanisms. *J Invest Dermatol* 2007;127:514–25.
- [4] Mahdavian Delavary B, van der Veer WM, van Egmond M, Niessen FB, Beelen RH. Macrophages in skin injury and repair. *Immunobiology* 2011;216:753–62.
- [5] Lakhan SE, Kirchgessner A. Anti-inflammatory effects of nicotine in obesity and ulcerative colitis. *J Transl Med* 2011;9:129.
- [6] Wang H, Yu M, Ochani M, Amella CA, Tanovic M, Susarla S, et al. Nicotinic acetylcholine receptor alpha7 subunit is an essential regulator of inflammation. *Nature* 2003;421:384–8.
- [7] Borovikova LV, Ivanova S, Zhang M, Yang H, Botchkina GI, Watkins LR, et al. Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin. *Nature* 2000;405:458–62.
- [8] Wang H, Liao H, Ochani M, Justiniani M, Lin X, Yang L, et al. Cholinergic agonists inhibit HMGB1 release and improve survival in experimental sepsis. *Nat Med* 2004;10:1216–21.
- [9] de Jonge WJ, van der Zanden EP, The FO, Bijlsma MF, van Westerloo DJ, Bannink RJ, et al. Stimulation of the vagus nerve attenuates macrophage activation by activating the Jak2-STAT3 signaling pathway. *Nat Immunol* 2005;6:844–51.
- [10] Saeed RW, Varma S, Peng-Nemeroff T, Sherry B, Balakhaneh D, Huston J, et al. Cholinergic stimulation blocks endothelial cell activation and leukocyte recruitment during inflammation. *J Exp Med* 2005;201:1113–23.
- [11] Heeschen C, Jang JJ, Weis M, Pathak A, Kaji S, Hu RS, et al. Nicotine stimulates angiogenesis and promotes tumor growth and atherosclerosis. *Nat Med* 2001;7:833–9.
- [12] Heeschen C, Weis M, Aicher A, Dimmeler S, Cooke JP. A novel angiogenic pathway mediated by non-neuronal nicotinic acetylcholine receptors. *J Clin Invest* 2002;110:527–36.
- [13] Misery L. Nicotine effects on skin: are they positive or negative? *Exp Dermatol* 2004;13:665–70.
- [14] Morimoto N, Takemoto S, Kawazoe T, Suzuki S. Nicotine at a low concentration promotes wound healing. *J Surg Res* 2008;145:199–204.
- [15] Jacobi J, Jang JJ, Sundram U, Dayoub H, Fajardo LF, Cooke JP. Nicotine accelerates angiogenesis and wound healing in genetically diabetic mice. *Am J Pathol* 2002;161:97–104.
- [16] Larson BJ, Longaker MT, Lorenz HP. Scarless fetal wound healing: a basic science review. *Plast Reconstr Surg* 2010;126:1172–80.
- [17] Deliaert AE, Van den Kerckhove E, Tuinder S, Noordzij SM, Dormaar TS, van der Hulst RR. Smoking and its effect on scar healing. *Eur J Plast Surg* 2012;35:421–4.
- [18] Carlsen H, Moskaug JO, Fromm SH, Blomhoff R. In vivo imaging of NF-kappa B activity. *J Immunol* 2002;168:1441–6.
- [19] Henningfield JE, Stapleton JM, Benowitz NL, Grayson RF, London ED. Higher levels of nicotine in arterial than in venous blood after cigarette smoking. *Drug Alcohol Depend* 1993;33:23–9.
- [20] Yoshikawa H, Kurokawa M, Ozaki N, Nara K, Atou K, Takada E, et al. Nicotine inhibits the production of proinflammatory mediators in human monocytes by suppression of I-kappaB phosphorylation and nuclear factor-kappaB transcriptional activity through nicotinic acetylcholine receptor alpha7. *Clin Exp Immunol* 2006;146:116–23.
- [21] Gilmore L. NF-kB Target Genes. Available: <http://www.bu.edu/nf-kb/gene-resources/target-genes/>.
- [22] van der Zanden EP, Snoek SA, Heinsbroek SE, Stanisor OI, Verseijden C, Boeckxstaens GE, et al. Vagus nerve activity augments intestinal macrophage phagocytosis via nicotinic acetylcholine receptor alpha4beta2. *Gastroenterology* 2009;137:1029–39 (39 e1–4).
- [23] Ulloa L. The vagus nerve and the nicotinic anti-inflammatory pathway. *Nat Rev Drug Discov* 2005;4:673–84.
- [24] Konishi H, Wu J, Cooke JP. Chronic exposure to nicotine impairs cholinergic angiogenesis. *Vasc Med* 2010;15:47–54.
- [25] Conklin BS, Zhao W, Zhong DS, Chen C. Nicotine and cotinine up-regulate vascular endothelial growth factor expression in endothelial cells. *Am J Pathol* 2002;160:413–8.
- [26] Zhen Y, Ruixing Y, Qi B, Jinzhen W. Nicotine potentiates vascular endothelial growth factor expression in balloon-injured rabbit aortas. *Growth Factors* 2008;26:284–92.
- [27] Kanda Y, Watanabe Y. Nicotine-induced vascular endothelial growth factor release via the EGFR-ERK pathway in rat vascular smooth muscle cells. *Life Sci* 2007;80:1409–14.
- [28] Ma L, Zwahlen RA, Zheng LW, Sham MH. Influence of nicotine on the biological activity of rabbit osteoblasts. *Clin Oral Implants Res* 2011;22:338–42.
- [29] Klettner AK, Doths J, Roeder J. Nicotine reduces VEGF-secretion and phagocytotic activity in porcine RPE. *Graefes Arch Clin Exp Ophthalmol* 2011;250:33–8.
- [30] Shi D, Guo W, Chen W, Fu L, Wang J, Tian Y, et al. Nicotine promotes proliferation of human nasopharyngeal carcinoma cells by regulating alpha7AChR, ERK, HIF-1alpha and VEGF/PEDF signaling. *PLoS One* 2012;7:e43898.
- [31] Lucas T, Waisman A, Ranjan R, Roes J, Krieg T, Muller W, et al. Differential roles of macrophages in diverse phases of skin repair. *J Immunol* 2010;184:3964–77.
- [32] Lau PP, Li L, Merched AJ, Zhang AL, Ko KW, Chan L. Nicotine induces proinflammatory responses in macrophages and the aorta leading to acceleration of atherosclerosis in low-density lipoprotein receptor(-/-) mice. *Arterioscler Thromb Vasc Biol* 2006;26:143–9.
- [33] Joe Y, Kim HJ, Kim S, Chung J, Ko MS, Lee WH, et al. Tristetraprolin mediates anti-inflammatory effects of nicotine in lipopolysaccharide-stimulated macrophages. *J Biol Chem* 2011;286:24735–42.
- [34] Kurzen H, Berger H, Jager C, Hartschuh W, Naher H, Gratchev A, et al. Phenotypical and molecular profiling of the extraneuronal cholinergic system of the skin. *J Invest Dermatol* 2004;123:937–49.
- [35] Fan YY, Yu TS, Wang T, Liu WW, Zhao R, Zhang ST, et al. Nicotinic acetylcholine receptor alpha7 subunit is time-dependently expressed in distinct cell types during skin wound healing in mice. *Histochem Cell Biol* 2011;135:375–87.

- 570 [36] Moser N, Mechawar N, Jones I, Gochberg-Sarver A, Orr-Urtreger A, Plomann
571 M, et al. Evaluating the suitability of nicotinic acetylcholine receptor
572 antibodies for standard immunodetection procedures. *J Neurochem*
573 2007;102:479–92.
- 574 [37] Herber DL, Severance EG, Cuevas J, Morgan D, Gordon MN. Biochemical and histo-
575 chemical evidence of nonspecific binding of alpha7nAChR antibodies to mouse
576 brain tissue. *J Histochem Cytochem* 2004;52:1367–76.
- 577 [38] Matsunaga K, Klein TW, Friedman H, Yamamoto Y. Involvement of nicotinic acetyl-
578 choline receptors in suppression of antimicrobial activity and cytokine responses of
579 alveolar macrophages to *Legionella pneumophila* infection by nicotine. *J Immunol*
580 2001;167:6518–24.
- 581 [39] Galvis G, Lips KS, Kummer W. Expression of nicotinic acetylcholine receptors on
582 murine alveolar macrophages. *J Mol Neurosci* 2006;30:107–8.
- [40] Zimmerman M, McGeachie J. The effect of nicotine on aortic endothelial cell turn- 583
over. An autoradiographic study. *Atherosclerosis* 1985;58:39–47. 584
- [41] Villablanca AC. Nicotine stimulates DNA synthesis and proliferation in vascular 585
endothelial cells in vitro. *J Appl Physiol* 1998;84:2089–98. 586
- [42] Ramp WK, Lenz LG, Galvin RJ. Nicotine inhibits collagen synthesis and alkaline phos- 587
phatase activity, but stimulates DNA synthesis in osteoblast-like cells. *Proc Soc Exp*
588 *Biol Med* 1991;197:36–43. 589
- [43] Mazhari NJ, Mandal AK, Thusoo TK. Carcinogenic effect of nicotine on normal mam- 590
mary ductal epithelial cells and the protective role of beta-carotene. *Indian J Pathol* 591
Microbiol 2003;46:24–7. 592
- [44] Ying X, Cheng S, Shen Y, Cheng X, An Rompis F, Wang W, et al. Nicotine promotes 593
proliferation and collagen synthesis of chondrocytes isolated from normal human 594
and osteoarthritis patients. *Mol Cell Biochem* 2012;359:263–9. 595
596

UNCORRECTED PROOF